Australia Diabetes Care Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Australia Diabetes Care Drugs Market is segmented by drugs (oral anti-diabetic drugs (Biguanides, Alpha-Glucosidase inhibitors, Dopamine D2 receptor agonists, SGLT-2 inhibitors, DPP-4 inhibitors, Sulfonylureas, and Meglitinides), insulin (Basal or long-acting insulins, bolus or fast-acting insulins, traditional human insulins, biosimilar insulins), non-insulin injectable drugs (GLP-1 receptor agonists and Amylin Analogue), and combination drugs (insulin combinations and oral combinations)). The report offers the value (in USD million) and Volume (in units million) for the above segments.

Australia Diabetes Care Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Australia Diabetes Care Drugs Industry Overview

The diabetes drugs market is moderately fragmented, with few significant generic players. A few major players, like Novo-Nordisk, Sanofi, AstraZeneca, and Bristol Myers Squibb, dominate the insulin drugs and Sglt-2 drugs market. The market for oral drugs, like Sulfonylureas and Meglitinides, comprises more generic players. The intensity of competition among the players is high, as each player is striving to develop new drugs and offer them at competitive pricing. Furthermore, players are tapping into new markets to increase their market shares. It is especially applicable in emerging economies where the demand is very high compared to the supply.

Australia Diabetes Care Drugs Market Leaders

  1. Eli Lilly

  2. Boehringer Ingelheim

  3. Astrazeneca

  4. Sanofi

  5. NovoNordisk

  6. *Disclaimer: Major Players sorted in no particular order
Australia Diabetes Care Drugs Market Concentration

Australia Diabetes Care Drugs Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?